NCT02702401View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

PHASE3CompletedINTERVENTIONAL
Enrollment

413

Participants

Timeline

Start Date

May 26, 2016

Primary Completion Date

January 2, 2019

Study Completion Date

September 22, 2021

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Placebo

0.90% w/v sodium chloride IV infusion

OTHER

Best Supportive Care

Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02702401 - Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Biotech Hunter | Biotech Hunter